Pathophysiology, Clinical consequences, Epidemiology and Treatment of Hyperurecemic gout
Abstract
Hyperuricemia is a common metabolic disorder worldwide with an increased level of serum urate/ uric acid (UA) up to 6.8 mg/Dl. It is a precursor of gout, a rheumatic inflammatory disease characterized by the deposition of uric acid in the form of monosodium urate (MSU) crystals in joints. It may be due to under secretion or over production or both. MSU crystals stimulated a powerful inflammatory reaction resulted in acute pain in joints. There are various marketed drugs used for the treatment of hyperuricemia i.e. allopurinol and Febuxostat .globally the prevalence of hyperurecemic gout is increasing day by day, it is 138th ranked factor of disability.it is more prevalent in male as compared to female and more present in developed countries than underdeveloped countries .it can be minimize by life style modification. Present attempt has been made to summarize the pathophysiology, clinical consequence, epidemiology and conventional treatment of hyperurecemic gout.
Copyright (c) 2018 RADS Journal of Pharmacy and Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Submitting a manuscript to a journal implies that the work has not previously been published in any other journal, printed or online (save as an abstract or an academic thesis), and that it is not currently being considered for publication elsewhere.
